YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Tenet Healthcare (THC) been one of those stocks this year? Let's take a closer look at the stock's year-to-date perform…
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Adicet Bio, Inc. (ACET) is a stock that can certainly grab the attention of many investors, but do its r…
You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know about: It's a healthcare investor. Joh…
Adicet Bio ACET continues to make steady progress with prula-cel/prulacabtagene leucel (formerly known as ADI-001),the company's lead product candidate and primary clinical value driver in autoimmune diseases. It is a first-in-class invest…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Adicet Bio, Inc. (ACET) is a stock that can certainly grab the attention of many investors, but do its…
SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the appointment…
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 28, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics…
(RTTNews) - Adicet Bio (ACET) said its board has approved a one-for-16 reverse stock split of the company's common stock as part of efforts to regain compliance with Nasdaq's minimum bid price requirement. The reverse split will take effec…
REDWOOD CITY, Calif., December 26, 2025--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today…
(RTTNews) - Several small-cap biotech and pharma names posted notable gains in Tuesday's after-hours trading session, with Nutex Health standing out as the most significant mover following its quarterly results. Nutex Health Inc. (NUTX) su…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Exact Sciences (EXAS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare…
* Adicet Bio (NASDAQ:ACET [https://seekingalpha.com/symbol/ACET]) announced an underwritten direct offering of 70 million shares of common stock and, for certain investors, pre-funded warrants to buy 10 million shares. * The common stock i…
MaxCyte, Inc. (NASDAQ:MXCT) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 4, MaxCyte, Inc. (NASDAQ:MXCT) announced signing a strategic platform license with Adicet Bio, Inc. Adicet focuses on developing allogeneic gamma…
Key Points No revenue reported as clinical programs remain in precommercial stages. Workforce and cost reductions are expected to extend cash runway into the fourth quarter of 2026.These 10 stocks could mint the next wave of millionaires ›…
(RTTNews) - Adicet Bio, Inc (ACET) will present in a fireside chat at the Jefferies Global Healthcare Conference, New York. The event is scheduled to begin at 4:20 PM ET on June 4, 2025. To access the live webcast, log on to https://invest…
REDWOOD CITY, Calif. & BOSTON, January 25, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer…
REDWOOD CITY, Calif. & BOSTON, January 23, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. ("Adicet") (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases…
REDWOOD CITY, Calif. & BOSTON, January 22, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. ("Adicet") (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases…
Key Insights Given the large stake in the stock by institutions, Adicet Bio's stock price might be vulnerable to their trading decisions 52% of the business is held by the top 6 shareholders Analyst forecasts along with ownership data serv…
Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to initiate Phase 1 clinical study in 2Q 2024 Focusing enrollment on mantle cell lymphoma (MCL) in o…
REDWOOD CITY, Calif. & BOSTON, January 03, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that t…
REDWOOD CITY, Calif. & BOSTON, December 29, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it gr…
ADI-001 showed robust dose-dependent expansion and persistence in patients with relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma (NHL) Strong exposure and persistence profile further supports Adicet’s allogeneic chimeric antige…
Initiated ADI-001 Phase 1 EXPAND cohort in post chimeric antigen receptor (CAR) T large B cell lymphoma (LBCL) Continuing to enroll mantle cell lymphoma (MCL) patients in ADI-001 Phase 1 study Prioritizing ADI-270 for solid tumor applicati…
REDWOOD CITY, Calif. & BOSTON, November 07, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that…
REDWOOD CITY, Calif. & BOSTON, November 02, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the a…
REDWOOD CITY, Calif. & BOSTON, October 31, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it gra…
Preclinical study shows Adicet’s Allogeneic Gamma Delta T Cell Platform may be a Promising Approach for Prostate Cancer REDWOOD CITY, Calif. & BOSTON, October 04, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage bio…
REDWOOD CITY, Calif. & BOSTON, September 29, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it g…
REDWOOD CITY, Calif. & BOSTON, September 27, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the…
Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a…
Announced encouraging safety and efficacy data in ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) On track to report a clinical update for ADI-001 in second half of…
REDWOOD CITY, Calif. & BOSTON, August 02, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Ch…
REDWOOD CITY, Calif. & BOSTON, July 31, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it grante…
REDWOOD CITY, Calif. & BOSTON, July 11, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the appoi…
REDWOOD CITY, Calif. & BOSTON, June 30, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it grante…